Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.

REDWOOD CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue ...

A follow-on study using a therapeutic isotope with HD6 will be presented at a future conference. "These results highlight the ability to tune our hydroxyl dendrimer platform to selectively target key ...

Cashin, MD, chief medical officer, Novotech, explores how CRO partnerships are shifting to deliver greater efficiency, ...

Cashin, MD, chief medical officer, Novotech, shares insights on how sponsors and CROs can cultivate a “one team” mindset by ...

CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives ...

Just missing the top five was sixth-ranked Atsena Therapeutics ($328 million, of which $150 million came from an oversubscribed Series C financing completed in January). Seventh-ranked Scribe ...

As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally.

North Carolina-based biotech Tune Therapeutics has raised $175 million in a Series B that will help it to take its lead epigenetic silencing drug, Tune-401, into clinical testing as a potential ...

CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded ...

Others raised warning flags about regulatory overreach, the threat of offshoring advanced therapeutics development to China, and the brain drain of young talent. Opening the roundtable discussion ...